These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27140986)

  • 1. Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure.
    Bennette CS; Richards C; Sullivan SD; Ramsey SD
    Health Aff (Millwood); 2016 May; 35(5):805-12. PubMed ID: 27140986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
    Gordon N; Stemmer SM; Greenberg D; Goldstein DA
    J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
    Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
    JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consumer Out-Of-Pocket Drug Prices Grew Faster Than Prices Faced By Insurers After Accounting For Rebates, 2007-20.
    Mallatt J; Dunn A; Fernando L
    Health Aff (Millwood); 2024 Sep; 43(9):1284-1289. PubMed ID: 39226496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rising cost of anticancer drugs in Australia.
    Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
    Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011.
    Shih YC; Smieliauskas F; Geynisman DM; Kelly RJ; Smith TJ
    J Clin Oncol; 2015 Jul; 33(19):2190-6. PubMed ID: 25987701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
    Michaeli DT; Michaeli T
    Pharmacoeconomics; 2024 Jan; 42(1):117-131. PubMed ID: 37855850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competition and price among brand-name drugs in the same class: A systematic review of the evidence.
    Sarpatwari A; DiBello J; Zakarian M; Najafzadeh M; Kesselheim AS
    PLoS Med; 2019 Jul; 16(7):e1002872. PubMed ID: 31361747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
    Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
    JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.
    Shih YT; Xu Y; Liu L; Smieliauskas F
    J Clin Oncol; 2017 Aug; 35(22):2482-2489. PubMed ID: 28471711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hidden cost of low prices: limited access to new drugs in India.
    Berndt ER; Cockburn IM
    Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.
    San-Juan-Rodriguez A; Gellad WF; Good CB; Hernandez I
    JAMA Netw Open; 2019 Dec; 2(12):e1917379. PubMed ID: 31834391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Drugs: An International Comparison of Postlicensing Price Inflation.
    Savage P; Mahmoud S; Patel Y; Kantarjian H
    J Oncol Pract; 2017 Jun; 13(6):e538-e542. PubMed ID: 28605615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing in the Market for Anticancer Drugs.
    Howard DH; Bach PB; Berndt ER; Conti RM
    J Econ Perspect; 2015; 29(1):139-62. PubMed ID: 28441702
    [No Abstract]   [Full Text] [Related]  

  • 17. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs.
    Ramsey SD
    Health Aff (Millwood); 2015 Apr; 34(4):571-5. PubMed ID: 25847638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
    Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
    Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.
    Kesselheim AS; Franklin JM; Kim SC; Seeger JD; Solomon DH
    J Gen Intern Med; 2015 Nov; 30(11):1633-8. PubMed ID: 25855479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of Cancer Drugs: Something Has To Give.
    Bender E
    Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.